Fulgent Genetics Inc Stock News

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.22 per share a year ago.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the

If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawr

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.78 per share a year ago.

Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential unde

Fulgent Genetics is seeing its base of revenue shift to non-COVID testing products. It's also starting to develop medicines in house after a recent acquisition.

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.

We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $4.93 per share a year ago.

If you're the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 bi

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.

Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brand